Special Session 31

3月27日［土］16:00-17:30

 
  cGMP research from bench to bedside
  
 
   
  The cGMP-PKG signaling pathway has emerged as a new therapeutic target for heart failure. Sacubitril/Valsartan (ARNI), Vericiguat (sGC stimulator) and PDE inhibitors all enhance cGMP-PKG, acting on nitric oxide (NO)-soluble guanylate cyclase (sGC) or natriuretic peptides (NPs)-particulate guanylate cyclase pathways. Importantly, the complexity of their pathway regulation leads to differential downstream molecular targets and thus physiological impacts. With the world-renowned experts in this field, this session will provide the cutting-edge of cGMP research. We will discuss how we should use cGMP-modifying interventions to best strategize heart failure treatment.
 
 
   
 
 
Eiki Takimoto   Eiki Takimoto
Department of Cardiovascular medicine, The University of Tokyo, Tokyo
   Burkert Pieske   Burkert Pieske
Medical Clinic with focus on Cardiology, Charite Universitatsmedizin Berlin, Berlin, Germany
 
 
   
 
 
Burkert Pieske   Burkert Pieske
Medical Clinic with focus on Cardiology, Charite Universitatsmedizin Berlin, Berlin, Germany
   Michaela Kuhn   Michaela Kuhn
Institute of Cardiovascular Physiology, University of Wuerzburg, Wuerzburg, Germany
 
 
 
Hitoshi Nakagawa   Hitoshi Nakagawa
Department of Cardiovascular Medicine, Nara Medical University, Kashihara
   Nobuaki Fukuma   Nobuaki Fukuma
Division of Cardiology, Medical Department, Columbia University Vagelos College of Physicians and Surgeons, New York, USA
 
 
 
Taishi Nakamura   Taishi Nakamura
Department of Medical Information Science and Administration Planning, Kumamoto University Hospital, Kumamoto